CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead

Table 2

CD19 CAR-T of clinical trial.

Study (reference)	Patient number	scFv	Costimulatory domain	Median age (range) (y)	CAR-T cell doses	Disease-related outcomes
Maude et al. (2014) [28]	30 ALL (25 children, 5 adults)	FMC63	4-1BB	Pediatric ALL: 11 (5–22); Adult ALL: 57 (36–60)		6-month EFS: 67%; 6-month OS: 78%; CR: 90% (MRD-negative in 88% of those who achieved CR)
Brentjens et al. (2011) [81]	8 CLL adults	SJ25C1	CD28	Adults CLL: 58 (67-48)	Cohort receiving no LDC: Cy cohort:	ORR: 1/8 (PR); two others with ≥2 months of SD, all in Cy cohort
Brudno et al. (2016) [80]	5 ALL	FMC63	CD28	Adults ALL: 25 (20-68)		CR: 80% (4/5, all MRD-negative)
Kochenderfer et al. (2015) [82]	5 CLL adults	FMC63	CD28	Adults CLL: 61(48-68)		CR: 60%
Lee et al. (2014) [76]	20 B-ALL	FMC63	CD28	Children and young adults: 15 (1-30)	CAR-transduced T cells per kg (dose 1); CAR-transduced T cells per kg (dose 2)	CR: 70% (MRD-negative in 86% of those who achieved CR); PD: 20% & SD: 10% (day 28)
Schuster et al. (2017) [18]	28 lymphomas	FMC63	4-1BB	Adult patients	Median total CTL019-cell: (range, to ); Median CTL019-cell: cells/kg (range, to cells/kg)	CR at 6 months: (57%; 95% CI, 37 to 76); CR: 57% median of 28.6 months (range, 3.5 to 37.9)

EFS: event-free survival; CLL: chronic lymphocytic leukemia; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.